NRx is a clinical-stage pharmaceutical company that is developing ZYESAMI (aviptadil acetate) for COVID-19 and NRX-101, the first oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder.

Biotechnology

NRx Pharmaceuticals

Stephen Willard

M. Daniel Gordin

Martin Brecher

Matthew Duffy

Rick Panicucci

Dennis K. McBride

Jonathan C. Javitt

Seth Van Voorhees

Philip T. Lavin

The executive team at NRx Pharmaceuticals has a history of working in the biotech industry and at Pfizer. They have experience in commercial development, marketing, and patient relations. They hold degrees in economics from Case Western Reserve University.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at NRx Pharmaceuticals

Leadership Team

Board of Directors